Industry
Medical - Care Facilities
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Loading...
Open
5.15
Mkt cap
345M
Volume
3.6M
High
6.04
P/E Ratio
-2.31
52-wk high
12.75
Low
4.97
Div yield
N/A
52-wk low
4.05
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 4:59 pm
Portfolio Pulse from Juan Spínelli
September 05, 2024 | 4:53 pm
Portfolio Pulse from Benzinga Newsdesk
August 23, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 7:54 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 10:33 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:18 pm
Portfolio Pulse from Benzinga Newsdesk
July 23, 2024 | 10:42 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.